Five years of fecal microbiota transplantation - an update of the Israeli experience

Table 5 Comparison of patients’ characteristics by age

	Valid	No.	Below 60 yr		Above 60 yr		P value
			Number	%	Number	%
Patients	111	111	35	31.52	76	68.5
Male gender	111	47	15	42.93	32	42.1	0.941
Ambulatory	111	78	30	85.73	48	63.2	0.011
CDI risk factors
Prior hospitalization	111	80	22	62.93	58	76.3	0.142
Antibiotics use	108	89	28	80.03	61	83.6	0.649
PPI usage	110	37	9	25.73	28	37.3	0.230
Chemotherapy	111	19	7	20.03	12	15.8	0.584
IBD	111	20	14	40.03	6	7.9	0.000
Steroid usage	111	17	9	25.73	8	10.5	0.039
Fever	76	21	7	35.03	14	25.0	0.391
Severe	111	20	3	8.63	17	22.4	0.079
Route
Lower GI	111	50	12	34.33	38	50.0	0.254
Upper GI1	111	24	8	22.93	16	21.1
Capsules	111	37	15	42.93	22	28.9
0-1 Previous CDI	107	24	8	22.93	16	22.2	0.941
2+ previous CDI	107	83	27	77.13	56	77.8
Indication
Refractory	111	29	8	22.93	21	27.6
Recurrent	111	82	27	77.13	55	72.4
Prior therapy
Metronidazole	110	98	29	82.93	69	80.0	0.722
Vancomycin	109	109	35	100.03	74	98.7	0.493
Combination	109	31	12	34.33	19	25.7	0.352
Outcomes
Success	111	97	33	94.33	64	84.2	0.137
Recurrence by 6 m	99	16	7	203	9	14.1	0.443
Death	111	11	0	03	11	100.0	0.018
Adverse events	107	19	5	14.33	14	19.4	0.512
			Mean	SD	Mean	SD	Sigma
Age (yr)	111		37.26	14.72	77.07	8.9	0.000
Charlson comorbidity score	81		1.29	1.95	6.35	2.3	0.000
Previous CDI episodes (n)	107		2.63	1.9	2.38	1.51	0.455
Time from 1st CDI (d)	89		198.75	279.04	102.68	112.19	0.024
Creatinine (mg/dL)	76		0.91	0.51	1.67	1.63	0.051
Albumin (mg/L)	54		3.51	0.99	3.17	0.69	0.153
WBC (103/dL)	76		11.33	90.36	14.78	19.86	0.468

¹Upper GI: Gastroscopy, nasogastric tube or through percutaneous endoscopic gastrostomy;

²Percentages refer to the total number of subjects in the cohort;

³Percentages refer to the number of subjects in the specific group. CDI: Clostridium difficile infection; IBD: Inflammatory bowel diseases; PPI: Proton pump inhibitor; GI: Gastrointestinal; FMT: Fecal microbiota implantation; IQR: Inter quartile range; WBC: White blood cells; Prior hospitalization: Hospitalization in the 3 mo prior to the FMT; Prior hospitalization: Antibiotics use in the 3 mo prior to the FMT.